Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07454681

MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure .

This study is being done to determine whether MRI can produce high quality lung and airway images in healthy and CF patients and if MRI can be used to evaluate size and shape of the airways with computer assistance. This study will also repeat MRI experiments two years after the initial MRI scan to see if changes to airway size and shape are seen over time. In a subset of participants, we will investigate whether MRI results are repeatable and reproducible in the short-term one week after the initial MRI visit. This study will help understand if MRI based measurements of airway size and shape can be used as a monitoring tool that does not use x-ray radiation in patients with CF.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Early CF disease in the lungs is characterized by repeated infection which can alter dimensions of the airways , especially abnormal dilation of the airways (bronchiectasis) Airway tree mapping is a form of quantitative imaging that investigates segmentation and dimensionality of the upper airways. CT detects utilized to characterize airway dimension in adults with COPD, but involves ionizing radiation. Unexplored in children.

MRI: Non-invasive, radiation-free, ideal for longitudinal monitoring. However, struggles with lung imaging due to low signal intensity, short T2 relaxation times, and motion artifacts Advanced ultrashort echo time (UTE) MRI enables high-resolution airway imaging with motion correction for free-breathing airway imaging. May permit airway tree mapping in children while obviating ionizing radiation risk.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Group 1

Inclusion criteria

  • Participants must be greater than or equal to 6 years of age and not greater than 18 years of age.
  • Informed consent by patient or parent/guardian consent and participant assent when appropriate.
  • Able to perform reproducible spirometry

Exclusion criteria

  • Medical instability that would preclude the ability to undergo the required investigations
  • FEV1 % predicted < 40%
  • Severe claustrophobia
  • Does not meet MRI screening criteria
  • Usage of oral antibiotics within 3 weeks prior to study visit
  • Known pulmonary disease

Group 2 Inclusion Criteria

  • Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen
  • Participants must be greater than or equal to 6 years of age and not greater than 18 years of age.
  • Informed consent by patient or parent/guardian consent and participant assent when appropriate.
  • Able to perform reproducible spirometry

Exclusion criteria

  • Medical instability that would preclude the ability to undergo the required investigations
  • FEV1 % predicted < 40%
  • Severe claustrophobia
  • Does not meet MRI screening criteria
  • Worsening cough and/or sputum production within the past 3 days prior to study visit
  • The use of new oral and/or inhaled antibiotics within 3 weeks prior to study visit
  • Received intravenous antibiotics within 2 weeks prior to study visit
  • The use of supplementary oxygen
  • Status of post lung or another organ transplant

Treatment and study plan

Advanced ultrashort echo time (UTE) MRI - Ultrashort echo time (UTE) imaging is a technique that can quickly capture the fast-decaying 1H lung signal.

Device

UTE lung MRI with various parameters will be done to determine optimal image quality for airway segmentation. The average scanning time for each sequence is in the order of 10 minutes.

Multiple Breath Wash out (MBW)

Device

Lung clearance index (LCI) will be determined by nitrogen multiple breath washout using the Exhalyzer D for measurement of inert gas washout. LCI measures will be taken in triplicate to ensure reproducibility.

Primary outcomes

  1. Airway Lumen Diameter measured by UTE MRI

    Time frame: Baseline (Visit 1A); Optional 1-week repeatability visit (Visit 1B) & 2-year follow-up (Visit 2A)

    Quantitative measurement of airway lumen diameter (millimeters) across airway generations 1-6 using UTE MRI airway tree segmentation.

Secondary outcomes

  1. Lung Clearance Index (LCI)

    Time frame: Baseline (Visit 1A); Optional 1-week repeatability visit (Visit 1B) & 2-year follow-up (Visit 2A)

    LCI measured with nitrogen Multiple Breath Washout (MBW).

Study contacts

Contact information is provided by the study sponsor or research team.

Sharon Braganza, MSc, CCRP

CONTACT

[email protected]

(416) 813-7654 ext. 307937

Sheryl Hewko, MSc, RN

CONTACT

[email protected]

416-813-7865

Sponsors and collaborators

Lead sponsor

The Hospital for Sick Children

Other

Registry information

Official study title

Development of Magnetic Resonance Imaging Airway Segmentation to Assess and Monitor Cystic Fibrosis Lung Disease

Acronym: UTE Airway MR

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Mar 6, 2026
Registry last updated
Mar 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.